Paclitaxel and vinorelbine combination in advanced inoperable adenocarcinoma of the lung: A phase II study

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3479-3484

  Stathopoulos, George P ^a,e   Veslemes, Marinos ^b   Georgatou, Niki ^b   Antoniou, Demosthenis ^b   Tsavdaridis, Dimitris ^c   Katis, Kostas ^d   Giaboudakis, Pantelis ^b   Rigatos, Sotiris K ^a   Marosis, Kostas ^b  

^a Errikos Dunant Hospital   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c B General IKA Hospital   (Greece)

^d THRIASIO GENERAL HOSPITAL   (Greece)

^e NONE   (Greece)

Author keywords

Adenocarcinoma; Paclitaxel; Vinorelbine

Indexed keywords

NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYTOPATHOLOGY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG RESPONSE; FEBRILE NEUTROPENIA; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INOPERABLE CANCER; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; VINBLASTINE;

EID: 0042028347     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Livingston RB: Combination chemotherapy of bronchogenic carcinoma, non-oat cell. Cancer Treat Rev 4: 153-165, 1997.
2. Ruckdeschel JC, Finkelstein DM, Mason BA et al: Chemotherapy for metastatic non-small cell bronchogenic carcinoma EST 2575, generation V-a randomized comparison of four cisplatin containing regimens. J Clin Oncol 3: 72-79, 1985.
3. Sadler AB, Nemunaitis J, Dehnam C et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18: 122-130, 2000.
4. Splinter TAW, Verhueven G, Hho GS et al: Neoadjuvant chemotherapy in stage 3 non-small-cell lung cancer (NSCLC). Evaluation response. Proceedings of ASCO 12: 359 (Abstr 1213), 1993.
5. Non-Small-Cell Lung Cancer Collaborative Groups: Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
6. Greco A and Hainsworth JD: Paclitaxel (1 hour infusion) plus carboplatin in the treatment of advanced non-small-cell lung cancer: results of a multicenter phase II trial. Semin Oncol 24 (suppl 12): 512-14s 12-17, 1997.
7. Belani CP, Keams CM, Zuhowski EG et al: Phase I trial including pharmacokinetic and pharmacodynamic correlations of combination paclitaxel and carboplatin in patients with metastatic non-small-cell-lung cancer. J Clin Oncol 17: 676-684, 1999.
8. Taffaioli RV, Tortoviello A, Facchini G et al: Phase I-II study of gemcitabine and carboplatin in stage IIIb-IV non-small-cell lung cancer. J Clin Oncol 17: 921-926, 1999.
9. Georgoulias V, Kouroussis Ch, Androulakis N et al: Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17: 914-920, 1999.
10. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 22: 665-669, 1979.
11. Manfredi JJ and Horwitz SB: Taxol. An antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-87, 1984.
12. Horwitz SB, Cohen D, Rao S et al: Taxol: mechanism of action and resistance. Monograph Natl Cancer Inst 15: 63-67, 1993.
13. Himes RH. Interactions of the Catharanthus (vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51: 256-59, 1991.
14. Jordan MA, Thrower D and Wilson L: Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51: 2212-17, 1991.
15. Cabral F, Wible L, Brenner S et al: Taxol-requiring mutants of Chinese hamster ovary cells with impaired mitotic spindle activity. J Cell Biol 97:(1) 30-39, 1983.
16. Rowinsky EK and Donehower RC: Drug therapy: paclitaxel (Taxol). N Engl J Med 332: 1004-1007, 1996.
17. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antineoplastic agent. J Natl Cancer Inst 82: 1247-1250, 1990.
18. Akerley W, Choy H, Safran H et al: Weekly paclitaxel in patients with advanced lung cancer. Preliminary data from a phase II trial. Semin Oncol 24 (Suppl. 12): s12-10-s12-13, 1997.
19. Miller VA, Krug LM, Ng KK et al: Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 1346-1350, 2000.
20. Stathopoulos GP, Rigatos SK, Pergantas N et al: Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20: 37-41, 2002.
21. Hitt R, Castellano D, Cortes-Funes H et al: Biweekly gemcitabine plus vinorelbine: A dose-finding phase I study in advanced cancer. Proceedings of ASCO 18: 214a, (Abstr 821), 1999.
22. Chang AY, Devore R and Johnson D: Pilot study of vinorelbine (Navelbine) and paclitaxel in patients with refractory non-small-cell lung cancer. Semin Oncol 23 (Suppl. 5):19-21, 1996.
23. Masters G, Liptay M, La Combe M et al: A phase I/II study of carboplatin and gemcitabine as induction chemotherapy followed by concurrent vinorelbine and paclitaxel with radiation in patients with stage III non-small-cell lung cancer. Lung Cancer 34 (Suppl. 1): sl-s69, (Abstr), 2001.
24. Breton JE, Westeel V, Jacoulet P et al: Phase I study of paclitaxel (Taxol) plus vinorelbine (Navelbine) in patients with untreated stage IIIb and IV non-small-cell lung cancer. Cancer 31: 295-301, 2001.
25. Perez JE, Machiavelli MR, Romero AO et al: Vinorelbine and paclitaxel for locoregional advanced or metastatic non-small-cell lung cancer. Am J Clin Oncol 25: 383-387, 2002.
26. Friedman EL, Straus MJ, Ambinder JM et al: Vinorelbine, paclitaxel and carboplatin (VPC) for adenocarcinoma of the lung. Proceedings of ASCO 17: 484a, (Abstr1861), 1998.
27. Rosati G, Rossi A, Nicoletta G and Panza N: Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pretreated sensitive cisplatin-based patients with advanced non-small cell lung cancer. Anticancer Res 20: 2229-2234, 2000.
28. Nguyen NP, Leonardo JM, Karlsson U, Vos P, Bullock L, Thomas P, Lepera P, Ludin A, Chu C, Salepour M, Jendrasiak G and Sallah S: Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma. Anticancer Res 22: 3429-3436, 2002.
29. Pectasides D, Fountzilas G, Rigopoulos A, Bountouroglou NG, Koutras A, Glotsos J, Onyenadum A, Makatsoris T and Kalofonos HP: Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. a phase II study of the Hellenic Cooperative Oncology Group. Anticancer Res 22: 3501-3506, 2002.
30. Recchia F, Lombardo M, De Filippis S, Rosselli M and Rea S: Gemcitabine, ifosfamide, and vinorelbine in advanced non-small cell lung cancer: a phase II study. Anticancer Res 22: 1321-1328, 2002.
31. Illiano A, Barletta E, De Marino V, Battiloro C, Barzelloni M, Scognamiglio F, Rossi N, Zampa G, De Bellis M and Gridelli C: New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non-small cell lung cancer: a phase II study. Anticancer Res 20: 3999-4004, 2000.